Literature DB >> 12004916

Insulin formulations--a review.

A M Gualandi-Signorini1, G Giorgi.   

Abstract

Although the improvement on insulin therapy since it was first conceived, it is still far from mimicking physiological secretion of pancreatic b-cells and research to find new insulin formulations and new routes of administration continues. Human biosynthetic insulin (rapid-acting, intermediate-acting and long-acting), produced by recombinant DNA technique, is currently available. The pharmacokinetic profile of rapid-acting insulin (regular) does not adequately reproduce the physiological post-prandial insulin response. This has led to the development of molecular analogues with slight modifications that prevent the spontaneous polymerisation underlying delayed absorption. Fast-acting analogues such as Lyspro and Aspart can be injected immediately before the meal, inducing a very fast and substantial peak of insulin, similar to that produced by b-cells, but have the disadvantage of short duration of action. For this reason, and because of the difficulty of obtaining sufficient basal insulin concentrations to control preprandial blood glucose levels with current long-acting insulins, analogues known as Glargine and Detemir have been synthesized. They have virtually no plasma peak and acts for about 24 h. These characteristics make it ideal to cover basal insulin requirement. With insulin analogues, it also seems possible to overcome the problem of intra- and inter-individual variability in absorption after subcutaneous injection. This variability is directly proportional to the duration of insulin action. Research into new routes of administration has led to production of inhaled insulin powder, soon to become commercially available. Insulin is absorbed through the lung alveoli. Trials to evaluate efficacy and toleration have shown that inhaled insulin has a similar kinetic profile to the fast-acting injected analogue and can therefore be used for mealtime requirement, combined with a single daily injection of long-acting insulin. Oral insulin is currently being studied in type 1 diabetes prevention with promising results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12004916

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

Review 1.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

2.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 3.  Protein aggregation and its impact on product quality.

Authors:  Christopher J Roberts
Journal:  Curr Opin Biotechnol       Date:  2014-08-28       Impact factor: 9.740

Review 4.  Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics.

Authors:  Masahiro Sakagami
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.

Authors:  A L McCall; L S Farhy
Journal:  Minerva Endocrinol       Date:  2013-06       Impact factor: 2.184

6.  The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study.

Authors:  Richeek Pradhan; Hui Yin; Oriana H Y Yu; Laurent Azoulay
Journal:  Drug Saf       Date:  2020-02       Impact factor: 5.606

Review 7.  Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy.

Authors:  Masahiro Sakagami; Peter R Byron
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 8.  Inhaled insulin: A "puff" than a "shot" before meals.

Authors:  Dick B S Brashier; Anjan Khadka; Tejus Anantharamu; Ashok Kumar Sharma; A K Gupta; Sushil Sharma; N Dahiya
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

9.  Degludec: the new ultra-long insulin analogue.

Authors:  Marcos Antonio Tambascia; Freddy Goldberg Eliaschewitz
Journal:  Diabetol Metab Syndr       Date:  2015-06-26       Impact factor: 3.320

10.  Glucose-regulated insulin production in the liver improves glycemic control in type 1 diabetic mice.

Authors:  Ting Zhang; H Henry Dong
Journal:  Mol Metab       Date:  2014-11-01       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.